Literature DB >> 3643850

Pharmacokinetics of naproxen in elderly patients.

R M McVerry, J Lethbridge, N Martin, S K Mukerjee, T Littler, R Tallis, R Sibeon, M L Orme.   

Abstract

The pharmacokinetics of naproxen have been examined in 13 elderly patients (mean age 84.2 years) and in 9 younger patients (mean age 53.9 years) at the end of a 21 day course of therapy with naproxen 500 mg b.d. The mean pre-dose concentration on days 19, 20 and 21 was significantly higher in the elderly patients than in the controls (60.1 vs. 43.3 micrograms X ml-1). The AUC (0-24) was significantly higher in the elderly subjects only when normalized for body weight (9.1 vs. 5.4 micrograms X ml-1 X h kg-1 p less than or equal to 0.02). The AUC was significantly higher in the elderly group compared to the control group also in the normalized form. The apparent clearance of naproxen was reduced in the elderly compared to the control patients (315 vs. 628 ml X h-1). The percentage protein binding of naproxen was the same in both groups (99.8%) but the free concentration of naproxen was significantly higher in the elderly patients than in the control patients (141 vs. 89.8 ng X ml-1). Although there was no excess of side effects in the elderly patients it is suggested that when naproxen is given to elderly patients, therapy should be started at the lower end of the dosage range.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3643850     DOI: 10.1007/BF00613525

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  [Pharmacokinetics of indomethacin in the aged].

Authors:  A Traeger; M Kunze; G Stein; H Ankermann
Journal:  Z Alternsforsch       Date:  1973

2.  Pharmacokinetic observations on piroxicam in young adult, middle-aged and elderly patients.

Authors:  A D Woolf; H J Rogers; I D Bradbrook; D Corless
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

3.  Fatal cholestatic jaundice in elderly patients taking benoxaprofen.

Authors:  H M Taggart; J M Alderdice
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-08

4.  Pharmacokinetic projections for isoxicam and piroxicam in old and young subjects.

Authors:  A J Campbell; D G Ferry; I R Edwards
Journal:  Br J Rheumatol       Date:  1985-05

5.  Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine.

Authors:  R A Upton; J N Buskin; R L Williams; N H Holford; S Riegelman
Journal:  J Pharm Sci       Date:  1980-11       Impact factor: 3.534

6.  A multi-centre study of sulindac versus naproxen in the treatment of elderly osteoarthritic patients.

Authors:  P G Janke; J B Diggins; W J Currie; P K Dasgupta; E N Glick; N A Sheikh
Journal:  Pharmatherapeutica       Date:  1984

7.  Naproxen pharmacokinetics in the elderly.

Authors:  R A Upton; R L Williams; J Kelly; R M Jones
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

8.  Osteoarthritis and non-steroidal and anti-inflammatory drugs: a multi-centre comparative study.

Authors:  M S Pathy
Journal:  Curr Med Res Opin       Date:  1982       Impact factor: 2.580

9.  Pharmacokinetics of azapropazone in the elderly.

Authors:  A E Ritch; W N Perera; C J Jones
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

10.  Oxaprozin pharmacokinetics in the elderly.

Authors:  D J Greenblatt; R Matlis; J M Scavone; G T Blyden; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

View more
  8 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Non-steroidal Anti-inflammatory Drugs: Monitoring to help prevent serious adverse effects.

Authors:  B Cardario; A A McKinnon
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

Review 3.  Switching drug availability from prescription only to over-the-counter status. Are elderly patients at increased risk?

Authors:  S I Benrimoj; J H Langford; M G Bowden; E J Triggs
Journal:  Drugs Aging       Date:  1995-10       Impact factor: 3.923

Review 4.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of naproxen.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

Review 6.  Tenoxicam and renal function.

Authors:  R C Heintz
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

Review 7.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

Review 8.  Free drug metabolic clearance in elderly people.

Authors:  Jennifer M Butler; Evan J Begg
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.